• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    1/2/24 8:05:43 AM ET
    $ADTX
    $CATX
    $CORT
    $ESLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ADTX alert in real time by email

    Gainers

    • Longboard Pharmaceuticals (NASDAQ:LBPH) shares increased by 157.0% to $15.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $369.7 million.
    • Cue Health (NASDAQ:HLTH) stock moved upwards by 40.61% to $0.23. The market value of their outstanding shares is at $35.3 million.
    • Voyager Therapeutics (NASDAQ:VYGR) stock rose 27.72% to $10.78. The market value of their outstanding shares is at $474.2 million.
    • NGM Biopharmaceuticals (NASDAQ:NGM) stock rose 26.89% to $1.09. The company's market cap stands at $90.1 million.
    • Estrella Immunopharma (NASDAQ:ESLA) stock rose 15.31% to $1.28. The market value of their outstanding shares is at $45.0 million.
    • Perspective Therapeutics (AMEX:CATX) shares rose 10.99% to $0.45. The market value of their outstanding shares is at $125.1 million.

    Losers

    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock declined by 32.8% to $2.67 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5 million.
    • Corcept Therapeutics (NASDAQ:CORT) stock decreased by 32.58% to $21.9. The company's market cap stands at $2.2 billion.
    • Aditxt (NASDAQ:ADTX) stock decreased by 26.85% to $4.85. The market value of their outstanding shares is at $2.1 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) stock fell 21.69% to $0.6. The company's market cap stands at $21.5 million.
    • LumiraDx (NASDAQ:LMDX) stock declined by 20.2% to $0.05. The company's market cap stands at $16.0 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) stock fell 17.93% to $1.74. The company's market cap stands at $14.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADTX
    $CATX
    $CORT
    $ESLA

    CompanyDatePrice TargetRatingAnalyst
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    Corcept Therapeutics Incorporated
    $CORT
    12/31/2025$30.00Peer Perform → Underperform
    Wolfe Research
    Corcept Therapeutics Incorporated
    $CORT
    12/16/2025Neutral
    UBS
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    Corcept Therapeutics Incorporated
    $CORT
    11/18/2025Peer Perform
    Wolfe Research
    Perspective Therapeutics Inc.
    $CATX
    10/10/2025$14.00Buy
    BTIG Research
    Perspective Therapeutics Inc.
    $CATX
    3/13/2025$10.00Buy
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    3/7/2025$15.00Sector Outperform
    Scotiabank
    More analyst ratings

    $ADTX
    $CATX
    $CORT
    $ESLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Corcept Therapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00

    12/31/25 9:53:16 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Corcept Therapeutics

    UBS initiated coverage of Corcept Therapeutics with a rating of Neutral

    12/16/25 8:47:55 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CATX
    $CORT
    $ESLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

    Achieved Intraclass Correlation Coefficient (ICC) of 0.89 with standard error of measurement (SEM) of 3.3% using independent operators ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced favorable results from a clinical study evaluating the measurement consistency of its TAEUS® Liver device. The study demonstrated the device's robust intra-user repeatability and inter-user reproducibility, essential factors for long-term monitoring of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which now affects approximately 30% of ad

    2/26/26 8:00:00 AM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

    Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals' marketing of a generic version of Korlym® does not infringe two of Corcept's patents concerning methods of safely co-administering Korlym and drugs that inhibit the CYP3A4 enzyme, including drugs that are commonly prescribed to patients with Cushing's syndrome. The ruling affirms a December 2023 verdict by the Federal D

    2/19/26 4:00:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CATX
    $CORT
    $ESLA
    SEC Filings

    View All

    SEC Form 144 filed by Voyager Therapeutics Inc.

    144 - Voyager Therapeutics, Inc. (0001640266) (Subject)

    2/24/26 5:10:03 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Voyager Therapeutics Inc.

    144 - Voyager Therapeutics, Inc. (0001640266) (Subject)

    2/24/26 5:09:40 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Corcept Therapeutics Incorporated

    10-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    2/24/26 4:13:38 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CATX
    $CORT
    $ESLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ADTX
    $CATX
    $CORT
    $ESLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ADTX
    $CATX
    $CORT
    $ESLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Spoor Johan M. bought $59,673 worth of shares (26,676 units at $2.24), increasing direct ownership by 59% to 59,383 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    4/1/25 6:44:41 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Officer Lyon Joseph Douglas

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    3/3/26 6:19:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Belanoff Joseph K

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    3/3/26 6:17:15 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Mokari Atabak

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    3/3/26 6:16:26 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CATX
    $CORT
    $ESLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Perspective Therapeutics Inc.

    SC 13G - Perspective Therapeutics, Inc. (0000728387) (Subject)

    11/14/24 6:14:40 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 6:13:11 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Voyager Therapeutics Inc.

    SC 13G/A - Voyager Therapeutics, Inc. (0001640266) (Subject)

    11/14/24 5:12:26 PM ET
    $VYGR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADTX
    $CATX
    $CORT
    $ESLA
    Leadership Updates

    Live Leadership Updates

    View All

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors

    SEATTLE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that its Board of Directors has appointed Maya Martinez-Davis as an independent director to the Company's Board of Directors, effective today. Ms. Martinez-Davis currently serves as President of GSK's U.S. Commercial business, a position she has held since September 2019. In that role, she leads a robust and complex business portfolio of products in specialty, respiratory, oncology and vaccines. Prior to GSK, Ms. Martinez-Davis was President of biopharma Latin

    9/3/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer

    Xaira is an integrated biotechnology company built to deliver on the promise of artificial intelligence to help transform drug discovery and development Jeff Jonker, a biotech industry veteran and former CEO of Belharra and Ambys Medicines, joins Xaira to help scale its AI-enabled drug discovery platform Xaira Therapeutics today announced the appointment of Jeff Jonker as President and Chief Operating Officer, reporting to CEO Marc Tessier-Lavigne. In this role, Jonker will work closely with Tessier-Lavigne to shape company strategy and drive the next phase of growth as Xaira builds the next generation of AI-driven drug discovery. He will be responsible for overseeing all operational fu

    7/9/25 12:00:00 PM ET
    $NGM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADTX
    $CATX
    $CORT
    $ESLA
    Financials

    Live finance-specific insights

    View All

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

    2025 revenue of $761.4 million Full year 2026 revenue guidance of $900 – $1,000 million 2025 net income of $99.7 million Cash and investments of $532.4 million at December 31, 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results "In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition among physicians of hypercortisolism's true pr

    2/24/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com.

    2/17/26 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care